CPhI Survey, Health News, ET HealthWorld

0


Noting that there is a steady growth in the pharmaceutical industry in India and the segment is improving in all key performance metrics of finished assay, API and biologics, the annual CPhI survey reported before the hybrid CPhI and P-mec event in India.

The 14th edition of CPhI & P-mec India will take place in a hybrid form, with an online conference and networking from November 15-30, as well as an in-person event in New Delhi from November 24-26.

Hosted by Informa Markets with attendees and exhibitors from around the world, both online and in person, the new CPhI analysis indicates continued growth in the pharmaceutical industry in India, with an improving outlook for the finished assay, l ‘API and biologics.

The India-specific results of the CPhI Annual Report survey were conducted among 350 executives, indicating a significant increase in the country’s global reputation, with India widely seen as benefiting from macroeconomic changes and the post-pandemic supply chain.

“There is a huge need for new manufacturing partners and, as the report shows, Indian manufacturers in particular are in high demand. By hosting a hybrid event and providing a platform where international and domestic buyers and suppliers can profile themselves, we facilitate greater opportunity for future partnerships, ”said Silvia Forroova, Brand Director, Informa.

India’s biggest metric improvement in CPhI data was in the perceived quality of “finished-dose manufacturing”, where the country jumped 13% in one year, adding to the 4% increase in 2020, while jointly surpassing the prestigious “growth”. potential ”with the United States for the first time.

In fact, in all of Indian manufacturing there has been tremendous growth over the past year.

Sriram Shrinivasan, consultant CHS Leader, Ernst & Young India, commented: “Indian contract manufacturing exported goods worth around $ 10 billion in 2020 and is expected to reach $ 27-28 billion by 2026, which equates to a fantastic 18-20% CAGR. during this period. In addition, there is more emphasis on outsourcing, resources and manufacturing in India. This trend is fueled by India’s reputation for quality, infrastructure, a growing innovation ecosystem and skilled workforce – one of the largest pools of STEM graduates in the world. world.

India has also seen its API manufacturing reputation improve by seven percent year over year. Highlighting this change in outlook, in 2021, private equity investments have increased fivefold [totalling $1.5billion] in API companies across the country. In fact, to help attendees explore this growing industry further, the second day of CPhI & P-mec India Online Conference will feature a live panel discussion on Next Generation APIs and Labs. The session will provide an overview of new possibilities for automation and robotics in pharmaceutical manufacturing, as well as an assessment of the complexity of the global API supply chain.

Another boon to Indian manufacturing, the country has shown the largest gains in terms of “growth potential for organic manufacturing” of any country – including traditional organic plants from France, the United States, Singapore and UK – possibly aided by the well from the Serum Institute of India. -documented supply of COVID vaccines.

An expert panel, moderated by Duncan Emerton, Executive Director, Custom Intelligence and Analytics, Informa Pharma Intelligence, will also explore the opportunities and challenges for biologics and biosimilars.

In order to enhance networking at the event, the online event platform will open more than a week before the in-person event begins, allowing the industry to maximize the value it shoots from CPhI & P-mec India in person. This allows businesses to identify more partners in advance and pre-qualify their prospects. The online platform will also host around thirty sessions spread over four sections: drug development and distribution, new generation APIs and laboratories, biosimilars and mAbs and digitization.

Alongside the event, India Pharma Week, which will host the “Women in Pharma” roundtable as well as the eighth annual India Pharma Awards.

Forroova added, “It is such an exciting time with a multitude of new opportunities emerging from India, which is why we are really looking forward to welcoming the hybrid CPhI & P-mec India. With so many networking opportunities over the course of the fortnight, I encourage everyone to take advantage of the online platform to not only host virtual meetings, but also to pre-qualify prospects before the in-person event. .


Leave A Reply

Your email address will not be published.